A recent industry-wide, independent market research study reveals that 64% of supply chain executives plan to increase their expenditure in clinical trial logistics in the next two years. The nature and complexity of new drugs and their protocols entering clinical development will increase their use of dedicated supply chain providers in the space. Temperature control capabilities (57%) and guaranteed on-time delivery within specifications (53%) as well as real-time traceability of shipments (49%) were the dominant reasons for companies moving to specialty providers such as Marken, which in April announced the completion of the study. The study shows that more than 50% reported that their organization had moved their clinical trials logistics business to a dedicated supply chain provider within the previous 24 months.
The survey included 250 key decision makers of clinical trial logistics services from pharmaceutical companies, central laboratories, clinical research organizations, and manufacturing service providers in North America, Central & South America, Europe, and Asia. Key topics profiled in the survey included market trends, industry pain points, and selection criteria for logistics providers.
Wes Wheeler, Marken’s Chief Executive Officer, says, “An increasing focus on rare diseases requires the industry to recruit patients from a larger pool of countries across the globe. The increased complexity of the drugs themselves, many of which are temperature-sensitive and of high value, tells us the service provided by a specialty courier such as Marken satisfies a critical need in the supply chain and the successful completion of each clinical trial. We were very pleased to reaffirm that our strategy aligns well with what our clients and potential clients need most.”
The survey was conducted by an outside firm familiar with the pharmaceutical outsourcing market and contains a significant amount of informative data on the industry, the key decision makers, and their decision-making criteria. Contact Jim Butschli for a full copy of the survey results.
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
